SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-142490
Filing Date
2021-11-22
Accepted
2021-11-22 16:15:18
Documents
4
Period of Report
2021-12-22

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2132544d2_def14a.htm DEF 14A 109932
2 GRAPHIC tm2132544d1_pre14aimg001.jpg GRAPHIC 4172
3 GRAPHIC tm2132544d1_pre14aimg01.jpg GRAPHIC 141650
4 GRAPHIC tm2132544d1_pre14aimg02.jpg GRAPHIC 211031
  Complete submission text file 0001104659-21-142490.txt   602992
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37558 | Film No.: 211432644
SIC: 2834 Pharmaceutical Preparations